Clinical Pharmacology of MDA [3,4-methylenedioxyamphetamine]

Status

Completed

Phases

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT00823407

Acronym

MDA

Enrollment

Registered

2009-01-15

Start date

2009-01-31

Completion date

2009-07-31

Last updated

2013-05-31

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Healthy

Keywords

MDA, MDMA, Ecstasy, entactogen, pharmacokinetics, pharmacodynamics, Pharmacokinetics and pharmacodynamics of MDA studies in healthy volunteers

Brief summary

The purpose of this study is to investigate the pharmacological and cognitive effects of MDA in healthy humans.

Interventions

DRUGMDA

subjects will receive a single oral dose of MDA 98mg/70kg body weight

DRUGPlacebo

Subjects will receive a single oral dose of placebo

Study design

Allocation

RANDOMIZED

Intervention model

SINGLE_GROUP

Primary purpose

BASIC_SCIENCE

Masking

DOUBLE (Subject, Caregiver)

Eligibility

Sex/Gender

ALL

Age

18 Years to 50 Years

Healthy volunteers

Yes

Inclusion criteria

* Healthy males and females age 18-50 * Fluent English speaker * Willing and able to give written consent

Exclusion criteria

* Body mass index \> 30 or \< 18 * Pregnancy or lactation FOR MORE DETAILS CONTACT THE RESEARCH CLINIC.

Design outcomes

Primary

Measure	Time frame
MDA will be metabolized to hydroxyamphetamine (HMA) and dihydroxyamphetamine (DHA) and will produce dose-dependent increases in neuroendocrine measures.	0-48 hours post dose

Secondary

Measure	Time frame
MDA will produce dose-dependent increases in self-report entactogen-like and stimulant like measures.	0-48 hours post dose

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Mar 30, 2026